A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID ‐19 Vaccinated Individuals
Journal of the Peripheral Nervous System · 2026-06 · 31 (2)
DOI: 10.1111/jns.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 29.03.2026. Verfasst von Luise Appeltshauser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Autoantibodies, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Gesellschaft für Muskelkranke, German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF), Julius-Maximilians-Universität Würzburg.
Abstract (Originalsprache)
Background and Aims Autoimmune nodopathy (AN) is a subtype of antibody‐mediated inflammatory neuropathy targeting the node of Ranvier (NoR). Diagnosis requires detection of anti‐(para)nodal autoantibodies like contactin‐1 and neurofascin‐155 via ELISA or cell‐based assays, but protocols are inconsistent. Causes of node autoimmunity are unknown, and respiratory infections, including SARS‐CoV‐2 infection or COVID‐19 vaccination as triggers, have not been thoroughly investigated. We aim to establish and validate a next‐generation automated ELISA for anti‐(para)nodal antibodies and investigate whether low‐titer antibodies occur in recently COVID‐19‐vaccinated healthy individuals.
Methods
We used the Ella platform to customize an automated ELISA for anti‐contactin‐1, −neurofascin‐155, and ‐Caspr‐1 serum IgG. Patients with known AN (23 anti‐neurofascin, 13 anti‐contactin‐1, and 8 anti‐Caspr‐1), 64 patients with seronegative (sub) acute inflammatory neuropathies, and 30 healthy controls served for validation, including quality analysis versus standard ELISA. Thirty‐seven diagnostic samples of patients with suspected AN and 280 sera of healthcare workers included in the CoVacSer study, collected 3 weeks after COVID‐19 vaccination or infection, were tested for anti‐contactin‐1 and anti‐neurofascin‐155.
Results
The automated ELISA showed high sensitivity (87.5%–100%) and specificity (98.4%–100%) for identifying AN, with reduced hands‐on time, high automation, and similar quality and titer characteristics as standard ELISA. Low‐titer anti‐neurofascin‐155, but no anti‐contactin‐1 autoantibodies, were detected in 1/280 post‐SARS‐CoV‐2‐vaccination or infection sera (0.36%). Longitudinal testing and clinical assessment did not indicate SARS‐CoV‐2‐related neurological symptoms.
Interpretation
We provide a highly automated, rapid, universally applicable test platform for anti‐(para)nodal antibodies. The low frequency of anti‐(para)nodal antibodies and absence of clinical AN manifestations in COVID‐19‐vaccinated individuals support vaccination safety regarding AN development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.
- Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Würzburg, Würzburg, Germany.
- Central Laboratory Unit, University Hospital Würzburg, Würzburg, Germany.
- Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Medicine, Centre for Interdisciplinary Pain Medicine, University Hospital Würzburg, Würzburg, Germany.
- Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
ORCID-Profile: Luise Appeltshauser, Juliane Mees
Förderung
- Deutsche Gesellschaft für Muskelkranke
- German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF)
- Julius-Maximilians-Universität Würzburg
Zitieren
APA
Appeltshauser, L., Ruprecht, C., Reusch, J., Mees, J., Glenewinkel, H., Sommer, C., Krone, M., Wagenhäuser, I., Doppler, K., & Petri, N. (2026). A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID ‐19 Vaccinated Individuals. Journal of the Peripheral Nervous System, 31(2). https://doi.org/10.1111/jns.70117
Vancouver
Appeltshauser L, Ruprecht C, Reusch J, Mees J, Glenewinkel H, Sommer C, et al. A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID ‐19 Vaccinated Individuals. Journal of the Peripheral Nervous System. 2026;31(2). doi:10.1111/jns.70117
BibTeX
@article{Appeltshauser2026,
author = {Appeltshauser, Luise and Ruprecht, Chiara and Reusch, Julia and Mees, Juliane and Glenewinkel, Helena and Sommer, Claudia and Krone, Manuel and Wagenhäuser, Isabell and Doppler, Kathrin and Petri, Nils},
title = {A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID ‐19 Vaccinated Individuals},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
volume = {31},
number = {2},
doi = {10.1111/jns.70117}
}
EUVIMED